BioSpace News Archive

Opthea Limited announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential initial public offering of American Depositary Shares in the U.S. representing Opthea’s ordinary shares, which will remain listed on the Australian Securities Exchange, and concurrent listing of the ADSs on the Nasdaq Stock Market.

Nuance Dragon Medical One cloud-based speech recognition solution reduces burden to clinicians and helps improve quality of available cancer data

Focus on Yumanity’s lead clinical program in Parkinson’s disease and transformative pipeline of disease-modifying treatments for neurogenerative disorders

Terumo Cardiovascular, a global leader in cardiovascular surgery technologies and subsidiary of Japan-based Terumo Corporation, and CytoSorbents Corporation, manufacturer of the CytoSorb® extracorporeal cytokine adsorber, announced an initial collaboration to exclusively sell CytoSorb to hospitals in ten U.S.

Humanigen, Inc. announced the appointment of Edward P. Jordan, MBA, to Chief Commercial Officer, a new role that will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, effective immediately.

Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases, today announced that they have entered into a definitive agreement under w

Humanigen, Inc., today announced the appointment of Edward P. Jordan, MBA, to Chief Commercial Officer, a new role that will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, effective immediately.

The global respiratory virus vaccines market was valued at US$ 2.6 Bn in 2019. It is projected to expand at a CAGR of ~8% from 2020 to 2030.

New data released by the Canadian Institute for Health Information shows that emergency department visits dropped by 25% in March 2020, compared with March 2019.

Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a sales agreement with a Texas-based laboratory to supply it with the necessary testing equipment and supplies for